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Fee Reduction
The Iowa Board of Pharmacy is pleased to announce that it 
will be lowering nearly all of its various license and registration 
fees by at least 10% during 2013. This action is required by 
Iowa Code, Section 147.80(2) so that Board revenues align more 
closely with Board expenditures. The Board will publish a new 
fee schedule as soon as it is available. Please watch the Board’s 
Web site for more information.
The Regulation of Compounding
The practice of pharmacy compounding, and particularly 
sterile compounding, has been the center of attention since the 
outbreak of fungal meningitis cases across the United States due 
to the distribution of contaminated products. At the center of the 
storm is a compounding pharmacy located in Massachusetts that 
holds an Iowa nonresident pharmacy license. The Board wishes 
to take this opportunity to remind all pharmacists who engage 
in sterile compounding of the importance of complying with 
the minimum standards of practice. The Board’s rules for sterile 
compounding practices can be found in 657 I.A.C. Chapter 13, 
which is a 13-page document. Chapter 13 incorporates most of 
the United States Pharmacopeia Chapter 797 standards and was 
adopted by the Board after a long and thoughtful process, with 
patient safety being the number one concern. While the Board 
supports compounding by pharmacies to meet unique patient 
needs, it has always taken the enforcement of sterile compound-
ing requirements very seriously. Between 1993 and 2012, the 
Board took formal disciplinary action in approximately 52 cases 
involving compounding and/or sterile compounding. Actions 
were taken against 18 pharmacies, 22 pharmacists, and two 
pharmacy technicians. In addition, eight emergency orders were 
issued. These cases involved a myriad of issues, including the 
compounding of inhalation/nebulizer products, intrathecal prod-
ucts, fertility products, and animal drug products; the preparation 
of commercially available products; the improper delegation of 
pharmacist functions to technicians; the lack of proper training; 
the lack of policies and procedures; and the absence of appro-
priate product testing. Some of the cases resulted in the closure 
of pharmacies or the discontinuance of compounding services. 
Of further concern are the out-of-state pharmacies that hold 
Iowa nonresident licenses and ship compounded products into 
Iowa. The Board estimates that it has as many as 200 com-
pounding pharmacies licensed outside of Iowa. In the past, 
the Board has relied on the home states of those pharmacies 
to conduct inspections and ensure compliance with all appli-
cable regulations. The Board is now exploring the feasibility 
of conducting out-of-state inspections under its own authority, 
with the goal of protecting Iowans from injurious products and 
harmful practices. Pharmacists and consumers who become 
aware of problems with any drug product are encouraged to file 
a report with the Board and with the Food and Drug Adminis-
tration through the MedWatch program, located online at www 
.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm.
False Patient Identities
It has recently been brought to the Board’s attention that some 
patients are providing false identification to physicians when 
obtaining prescriptions for controlled substances, thereby cir-
cumventing the prescription monitoring program. Pharmacists 
are encouraged to request a government-issued photo ID from 
patients who pick up prescriptions for controlled substances, 
particularly those patients who are not known by the pharmacist.
DEA Prohibits Pharmacies from Sending 
Pre-Populated Prescriptions
The US Drug Enforcement Administration (DEA) recently 
interpreted the legality of pharmacies that serve nursing homes 
sending letters to physicians reminding them that a controlled 
substance (CS) prescription for a patient had run out or no longer 
had refills. DEA confirmed that reminder letters are permissible 
and can provide the prescriber with the patient’s name, the drug 
name, and other relevant prescribing information. However, 
the letter cannot pre-populate any of the fields in the actual 
prescription to be transmitted to the pharmacy. DEA stated that, 
“ . . . a pharmacy may not initiate a reminder letter to a prescribing 
practitioner that provides a partially or fully pre-populated form 
for the prescribing practitioner because the practitioner has not 
yet made the determination, in the usual course of professional 
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macist reads the warning, bypasses it, and dispenses the medication as 
entered. The patient receives an overdose of the medication and dies.
This error, and many more, have happened because the person 
performing the task fails to see what should have been plainly visible, 
and later, they cannot explain the lapse.1 People involved in these er-
rors have been labeled as careless and negligent. But these types of 
accidents are common – even with intelligent, vigilant, and attentive 
people. The cause is usually rooted in inattentional blindness.1 
Accidents happen when attention mistakenly filters away important 
information and the brain fills in the gaps with what is aptly referred 
to as a “grand illusion.”2 Thus, in the example above, the brain of the 
pharmacist filtered out important information on the computer screen, 
and filled in the gaps with erroneous information that led him to believe 
he had read the warning appropriately. 
Inattentional blindness is more likely to occur if part of your at-
tention is diverted to secondary tasks, like answering the phone while 
entering prescriptions into the computer, or even thinking about your 
dinner plans while transcribing an order. 
Low workload causes boredom and reduces the mental attention 
given to tasks, as does carrying out highly practiced tasks, such as 
counting out medication. We spend a large majority of our waking life 
functioning with the equivalent of an automatic pilot, with occasional 
conscious checks to ensure tasks are being carried out properly. This 
makes us particularly prone to inattentional blindness. 
Our past experiences also teach us what is relevant. Errors occur 
when new or unusual circumstances happen in highly familiar situ-
ations. The pharmacist who did not notice important information on 
a computer warning had rarely encountered a clinically significant 
computer alert. The pharmacist had subconsciously learned that there 
was nothing important to see when reading alerts. Nothing had ever 
happened, so attention was automatically filtered away from the details 
to conserve mental processing.  
Conspicuity is the degree to which an object or piece of informa-
tion “jumps out” and captures your attention. The best way to achieve 
this effect is through use of contrast, color, or shape to call attention 
to differences in packaging or text.
It is difficult to reduce the risk of inattentional blindness, as it is 
an involuntary and unnoticed consequence of our adaptive ability to 
defend against information overload. Error-reduction strategies such 
as education, training, and rules are of little value. Instead, efforts 
should center on increasing conspicuity of critical information, and 
decreasing diversions of attention and secondary tasks when carrying 
out complex tasks.         
1. Green M. “Inattentional blindness” and conspicuity. Visual Expert. 
2004. Accessed at www.visualexpert.com/Resources/inattentional 
blindness.html, March 1, 2012.
2. Angier N. Blind to change, even as it stares us in the face. The 
New York Times. April 1, 2008.
Know Your Dose Game Teaches Safe 
Acetaminophen Use
As part of the Know Your Dose campaign, the Acetaminophen 
Awareness Coalition has developed an interactive educational game 
to teach safe use of acetaminophen. The game not only answers some 
of the most common questions surrounding the safe use of acetamino-
phen, it gives an engaging face to the issue. The game, available on the 
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AHRQ Toolset Can Assist Pharmacies Using 
e-Prescribing 
A toolset released by the Agency for Healthcare Research and 
Quality (AHRQ) can assist independent pharmacies with the imple-
mentation of e-prescribing and may also provide useful guidance 
to those pharmacies already using e-prescribing. The toolset for 
independent pharmacies consists of seven chapters that provide guid-
ance on topics ranging from planning the implementation process 
and launching the system, to troubleshooting common problems 
and moving into more advanced pharmacy services, states AHRQ. 
Flyers for use in communicating the launch to patients, templates 
for communicating with providers about the launch, tools for as-
sessing pharmacy workflow, and a spreadsheet to determine return-
on-investment, among other tools, are also available to pharmacies. 
The toolset can be downloaded from the AHRQ Web site at http://
healthit.ahrq.gov/portal/server.pt/community/health_it_tools_and_
resources/919/a_toolset_for_e-prescribing_implementation_in_ 
independent_pharmacies/30595.
FDA Database Provides Information on Pediatric 
Medications 
A Food and Drug Administration (FDA) database provides in-
formation on pediatric medications, making it easier for both health 
care providers and caregivers to locate this information. The Pediatric 
Labeling Information Database is a one-stop resource, where providers 
and caregivers can search for information by the product’s commercial 
or chemical name, or by the condition for which it was studied. The 
database was developed by FDA’s Office of Pediatric Therapeutics 
(OPT), in collaboration with the Center for Drug Evaluation and Re-
search. The OPT also provides a Safety Reporting page with informa-
tion on products that have been tied to safety problems that specifically 
relate to children. Additional information and a link to the database 
is available in the Consumer Updates section of the FDA Web site 
at www.fda.gov/ForConsumers/ConsumerUpdates/ucm305040.htm. 
Inattentional Blindness: What Captures Your 
Attention?
This column was prepared by the Insti-
tute for Safe Medication Practices (ISMP). 
ISMP is an independent nonprofit agency 
that analyzes medication errors, near 
misses, and potentially hazardous condi-
tions as reported by pharmacists and other 
practitioners. ISMP then makes appropriate contacts with companies 
and regulators, gathers expert opinion about prevention measures, 
and publishes its recommendations. To read about the risk reduction 
strategies that you can put into practice today, subscribe to ISMP 
Medication Safety Alert!® Community/Ambulatory Care Edition by 
visiting www.ismp.org. ISMP is a federally certified patient safety or-
ganization, providing legal protection and confidentiality for submitted 
patient safety data and error reports. ISMP is also an FDA MedWatch 
partner. Call 1-800/FAIL-SAF(E) to report medication errors to the 
ISMP Medication Errors Reporting Program or report online at www.
ismp.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, PA 
19044. Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
A pharmacist enters a prescription for methotrexate daily into the 
pharmacy computer. A dose warning appears on the screen. The phar-
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Know Your Dose Web site at www.knowyourdose.org/game, invites 
consumers to follow three characters through a typical day of aches 
and pains while helping the characters learn how to take medicine that 
contains acetaminophen safely.
Contraception Products Sold Online With No 
Prescription Required, Endangering Public Health 
Health care providers should help to educate patients about the 
risks of prescription contraceptive products marketed online as “no 
prescription” and “over-the-counter” products, pharmaceutical security 
researchers conclude. A study by these researchers found that Google 
searches returned results for prescription contraceptive products such 
as injections, oral contraceptives, and patches, as well as intrauterine 
devices (IUDs). All of these products were marketed as available 
without a prescription and researchers found that sellers provided links 
to YouTube videos with IUD instructions. The researchers also found 
that these products were being promoted on social media channels, 
including Facebook, Twitter, SlideShare, and Flickr. Researchers Bryan 
A. Liang, MD, JD, PhD, Tim K. Mackey, MAS, and Kimberly M. 
Lovett, MD, conclude that such online contraceptive sales represent 
patient safety risks and also suggest that policy makers should “employ 
legal strategies to address these systemic risks.” The study, “Suspect 
Online Sellers and Contraceptive Access,” is available in the May 25, 
2012 issue of Contraception.
New FDA Drug Info Rounds Training Video 
FDA Drug Info Rounds, a series of online training videos, provides 
important and timely drug information to practicing clinical and com-
munity pharmacists so they can help patients make better medication 
decisions. In the latest Drug Info Rounds video, available at www.fda 
.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm313768.htm, 
pharmacists discuss the Accelerated Approval Program and how FDA 
helps make new, potentially lifesaving drugs available more quickly. 
Drug Info Rounds is developed with contributions from pharmacists 
in FDA’s Center for Drug Evaluation and Research, Office of Com-
munications, and Division of Drug Information. 
FDA Resources Help Raise Awareness About 
Health Fraud Scams
To help raise consumer awareness about health fraud scams, FDA 
provides numerous educational resources in the Health Fraud Scams 
section of its Web site. Educating consumers on how to avoid such 
scams, FDA videos present information on various types of fraudulent 
products such as fake diet, sexual enhancement, and body building 
products. Consumers can also access information about specific 
products that are the subject of FDA warning letters, recalls, public 
notifications, and safety alerts. FDA news releases related to health 
fraud are also accessible through this section of the Web site.
NABP Accepting Award Nominations for 109th 
Annual Meeting
The National Association of Boards of Pharmacy® (NABP®) is cur-
rently accepting nominations for the Association’s 2013 awards that 
will be presented during the 109th Annual Meeting, to be held May 
18-21, 2013, at the Hyatt Regency St Louis at the Arch in St Louis, MO.
Nominations are currently being accepted for the following awards: 
2013 Lester E. Hosto Distinguished Service Award (DSA), 2013 
NABP Honorary President, 2013 Fred T. Mahaffey Award, and 2013 
John F. Atkinson Service Award. 
Nominations for these awards must be received at NABP Head-
quarters no later than December 31, 2012. New this year, individuals 
wanting to submit a nomination will be asked to fill out and complete 
a nomination form, which may be accessed by visiting the Meetings 
section on the NABP Web site at www.nabp.net/meetings. Criteria for 
award nominees will also be posted to the Web site. Nomination forms 
should be sent to the NABP Executive Director/Secretary Carmen A. 
Catizone at NABP Headquarters, 1600 Feehanville Dr, Mount Pros-
pect, IL 60056. Directions for electronic submission will be available 
on the online form. The NABP Executive Committee will review the 
nominations and select the award recipients.
For more information, please contact the NABP Executive Office 
via e-mail at exec-office@nabp.net.
NABP Looking for Exam and Assessment  
Item Writers
NABP is seeking individuals to serve as item writers for the North 
American Pharmacist Licensure Examination®, the Multistate Phar-
macy Jurisprudence Examination®, the Foreign Pharmacy Graduate 
Equivalency Examination®, the Pharmacy Curriculum Outcomes 
Assessment®, and the Pharmacist Assessment for Remediation 
EvaluationSM. Pharmacists in all areas of practice, and faculty from 
schools and colleges of pharmacy are encouraged to apply. Interested 
individuals should e-mail, fax, or mail a letter of interest indicating 
their current practice/educational setting, specialties/certifications, and 
years of experience, along with a résumé or curriculum vitae:
 ♦ via e-mail at exec-office@nabp.net;
 ♦ via fax at 847/391-4502; or
 ♦ via mail to NABP Executive Director/Secretary Carmen A. Catizone 
at 1600 Feehanville Drive, Mount Prospect, IL 60056.
Please note, applications are accepted on a continuous basis and 
kept on file for a period of five years. For more information about item 
writing, contact NABP at custserv@nabp.net. Additional information 
may also be found in the August 2012 NABP Newsletter. 
 
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile and  
Register for CPE Monitor Today!
CPE Monitor™ integration is underway. Soon all Accreditation 
Council for Pharmacy Education (ACPE)-accredited providers will 
require you to submit your NABP e-Profile ID, assigned when you 
set up your NABP e-Profile, along with your date of birth (MMDD), 
in order to obtain continuing pharmacy education (CPE) credit for 
any ACPE-accredited activity. Many have already begun to do so.
Visit www.MyCPEmonitor.net to set up your e-Profile and register 
for CPE Monitor and avoid possible delays in your CPE reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
National Association of Boards of Pharmacy Foundation, Inc
1600 Feehanville Drive
Mount Prospect, IL 60056
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practice, that there is a legitimate medical purpose for the pre-
scription.” Pharmacists should be aware of DEA guidance on this 
issue and ensure appropriate compliance with DEA’s regulations 
on prescriptions and related regulations and laws.
NABP Field Services Assists with Iowa 
Inspections 
The Board has partnered with the National Association of 
Boards of Pharmacy® (NABP®) Field Services Department to 
assist Board staff with inspections and surveys in Iowa. Launched 
in 2011, an inspection and education program for controlled drug 
registrants is helping to ensure that CS are managed properly by 
registrants. NABP surveyors were trained to evaluate compliance 
with Iowa’s criteria, and conducted inspections using official 
Board forms. During a pilot of 50 registrants in 2011, NABP 
surveyors inspected CS registrant sites as assigned by the Board, 
and surveyed to ensure that CS drugs are handled, stored, and 
tracked in compliance with federal laws and Iowa requirements. 
During the first six months of 2012, NABP staff surveyed 500 CS 
registrants in central Iowa. NABP surveyors checked licenses, 
drug documentation, and drug inventories. They also provided 
education and training to some registrants. The Board has 
also partnered with NABP to provide a program for surveying 
pharmacy dispensing practices to ensure that patient care and 
dispensing services provided by Iowa pharmacies meet state 
requirements. NABP surveyors visit pharmacies, present valid 
prescriptions to be filled, and make observations about the entire 
dispensing process. Elements evaluated include whether a patient 
history was obtained; whether patient counseling services were 
provided by the dispensing pharmacist; whether the pharmacy 
adhered to Health Insurance Portability and Accountability 
Act requirements; and whether the prescription was dispensed 
accurately.
Board Meeting Dates for 2013
The Board will meet in regular session on the following dates 
in 2013: 
 ♦ January 15-16, 2013
 ♦ March 12-13, 2013
 ♦ April 23-24, 2013
 ♦ June 25-26, 2013
 ♦ August 27-28, 2013
 ♦ November 5-6, 2013
All meetings will be at the Board office in Des Moines, IA. 
Please contact the office at 515/281-5944 to confirm.
Board Web Site
Please visit the Board’s Web site at www.state.ia.us/ibpe/. 
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and 
protects the public health, safety, and welfare through the ef-
fective regulation of the practice of pharmacy and the licensing 
of pharmacies, pharmacists, and others engaged in the sale, 
delivery, or distribution of prescription drugs and devices. Iowa 
Code §155A.2(1).
Happy Holidays
The Board members and staff wish everyone a safe and happy 
holiday season.
Follow the Board on Facebook and Twitter
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
http://twitter.com/#!/IABoardPharmacy
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